- $26.42m
- $10.72m
- $0.01m
- 14
- 34
- 57
- 27
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 5.48 | ||
| Price to Sales | 2,701.27 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -624.41% | ||
| Return on Equity | n/a | ||
| Operating Margin | -31412.17% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 10 | 2.81 | 0.01 | 1.1 | 21.05 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.
Directors
- William Rastetter NEC (73)
- Sabrina Johnson PRE (55)
- Lisa Walters-Hoffert CFO (62)
- John Fair OTH (50)
- Cheryl Blanchard IND (56)
- Jessica Grossman IND (49)
- Susan Kelley IND (66)
- Gregory Matz IND (61)
- Sophia Ononye-Onyia IND (37)
- Robin Steele IND (65)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 28th, 2005
- Public Since
- April 10th, 2014
- No. of Shareholders
- 34
- No. of Employees
- 21
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 8,850,386
- Address
- 3655 Nobel Dr Ste 260, SAN DIEGO, 92122-1050
- Web
- https://www.darebioscience.com/
- Phone
- +1 8589267655
- Auditors
- Mayer Hoffman & McCann P.C.
Latest News for DARE
Upcoming Events for DARE
Dare Bioscience Inc at Fierce Pharma Engage
Q1 2025 Dare Bioscience Inc Earnings Release
Dare Bioscience Inc Annual Shareholders Meeting
Dare Bioscience Inc Annual Shareholders Meeting
Q2 2025 Dare Bioscience Inc Earnings Release
Similar to DARE
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
ASP Isotopes
NASDAQ Capital Market
FAQ
As of Today at 20:10 UTC, shares in Dare Bioscience are trading at $2.99. This share price information is delayed by 15 minutes.
Shares in Dare Bioscience last closed at $2.99 and the price had moved by -13.99% over the past 365 days. In terms of relative price strength the Dare Bioscience share price has underperformed the S&P500 Index by -20.61% over the past year.
The overall consensus recommendation for Dare Bioscience is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreDare Bioscience does not currently pay a dividend.
Dare Bioscience does not currently pay a dividend.
Dare Bioscience does not currently pay a dividend.
To buy shares in Dare Bioscience you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.99, shares in Dare Bioscience had a market capitalisation of $26.42m.
Here are the trading details for Dare Bioscience:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: DARE
Based on an overall assessment of its quality, value and momentum Dare Bioscience is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Dare Bioscience is $13.33. That is 346.57% above the last closing price of $2.99.
Analysts covering Dare Bioscience currently have a consensus Earnings Per Share (EPS) forecast of -$2.02 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Dare Bioscience. Over the past six months, its share price has underperformed the S&P500 Index by -13.8%.
As of the last closing price of $2.99, shares in Dare Bioscience were trading -9.54% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Dare Bioscience PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.99.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Dare Bioscience's management team is headed by:
- William Rastetter - NEC
- Sabrina Johnson - PRE
- Lisa Walters-Hoffert - CFO
- John Fair - OTH
- Cheryl Blanchard - IND
- Jessica Grossman - IND
- Susan Kelley - IND
- Gregory Matz - IND
- Sophia Ononye-Onyia - IND
- Robin Steele - IND